Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.
about
TPO/Mpl Studies in Agnogenic Myeloid MetaplasiaBone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-βGuidelines for the management of myeloproliferative neoplasmsThe Hen or the Egg: Inflammatory Aspects of Murine MPN ModelsImmunofluorescence and confocal laser scanning microscopy of chronic myeloproliferative disorders on archival formaldehyde-fixed bone marrow.In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.Immunomodulatory agents in myelofibrosis.Immune thrombocytopenia in postpolythemic myelofibrosis.Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinibReplacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis.Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications.Pathogenesis of idiopathic myelofibrosis: role of growth factorsTargeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study.Pathogenesis of Idiopathic Myelofibrosis: A Review.Platelet PDGF and TGF-β Levels in Myeloproliferative Disorders.The role of the extracellular matrix in primary myelofibrosis.The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.Current perspective in agnogenic myeloid metaplasia.Agnogenic myeloid metaplasia.Platelet-derived growth factor release and antiplatelet treatment with low-dose acetylsalicylic acid.A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia.Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide.Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the QuiverParticipação das plaquetas no processo de fibrose dos pacientes com esquistossomose mansônica
P2860
Q24805242-BAADD657-0F00-4BF4-9854-295459189ADBQ26745943-C65A0E2D-5B51-4344-8F7C-E4F18EE88A19Q26778326-B39BD7DD-4FDD-4B5E-878E-8DC687963E50Q26778931-4D6AEB86-31C1-48AA-801A-579CA413F90EQ33198294-1509413D-09D5-4E81-9F61-B2F481436D90Q33348021-A2CBF0FB-1DEA-4610-941B-E3747029014EQ33401615-C524C0BE-8D35-42BB-A325-C15986453C58Q33498469-687C347C-71DF-4C53-A27F-1A5C7B018B47Q35732435-64DADF48-72B0-4C9D-B8F4-EDDE0B5F28C6Q36012537-50F04C9E-3520-43CC-AE81-A202E7A3E32EQ36116382-15D48D04-72C3-48D1-A920-3CA1E67A2938Q36295209-53BDFB1C-59C3-4638-93AE-2766BFA20613Q36359558-07391E1A-8900-42E1-875F-27D583ABC120Q38404833-650564CD-FDDB-418E-B69B-FB9BD16B1FC8Q38896695-F6C8D8BB-2CDD-4DF4-B689-7E441159D29EQ38908421-1BB5C754-A0B0-4A10-9D6F-DAF8BF3F486AQ39117766-5EC99427-4364-4183-BE29-863119461308Q39451293-77F1F458-D24C-432E-8A0D-AD6DE03CF4C5Q41072991-EC946FA6-0F38-435C-939F-02E06FFAB452Q41253215-593667EA-672E-4C62-9B14-6408765B0B9BQ41421730-D31B2367-BA94-47CC-B7F0-DFE038F5EE82Q42288090-D075967E-2EFE-4F74-9627-488F1C72413AQ43687393-D6867146-C6A2-445D-9447-054D789E6FAEQ44059763-7C3456CB-5291-4F9A-BAE1-736BB5F88488Q44667229-475F0B76-4AD8-48DE-88D4-54746ABC97E6Q58701086-B82DE901-BD9C-4008-BE89-11550F4909E6Q58850401-154A7CA9-CE14-4697-8B65-287E3815730C
P2860
Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Increased intraplatelet levels ...... rosis with myeloid metaplasia.
@en
Increased intraplatelet levels ...... rosis with myeloid metaplasia.
@nl
type
label
Increased intraplatelet levels ...... rosis with myeloid metaplasia.
@en
Increased intraplatelet levels ...... rosis with myeloid metaplasia.
@nl
prefLabel
Increased intraplatelet levels ...... rosis with myeloid metaplasia.
@en
Increased intraplatelet levels ...... rosis with myeloid metaplasia.
@nl
P2093
P2860
P1476
Increased intraplatelet levels ...... rosis with myeloid metaplasia.
@en
P2093
Bryckaert MC
Laine-Bidron C
Magdelenat H
Martyré MC
P2860
P356
10.1111/J.1365-2141.1991.TB07952.X
P407
P577
1991-01-01T00:00:00Z